X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Four reasons why the radical Pelosi Plan is the wrong approach

By Tom Wilbur  |    September 24, 2019
Speaker of the House Nancy Pelosi recently unveiled a radical plan that would restrict and fundamentally change how patients access medicines in the United States. It would threaten our country’s...   Read More

Three reasons the Senate Finance package is the wrong approach for patients

By Tom Wilbur  |    August 26, 2019
For more than a decade, Medicare Part D has successfully provided seniors and people with disabilities comprehensive prescription drug coverage, while its unique market-based structure has kept...   Read More

New analysis: Government intervention in Part B threatens patient access to medicines

By Nicole Longo  |    August 19, 2019
A new analysis from Avalere looked at how access to medicines in Part B may be impacted if the government only covered a certain list of medicines, an approach known as applying a national...   Read More

No matter how you structure it, government arbitration is wrong for Medicare drug coverage

By Nicole Longo  |    June 27, 2019
Despite concerns from a broad group of stakeholders, some in Washington continue to push for imposing government arbitration on Medicare drug coverage to set the price of a medicine....   Read More

What you should know: Government arbitration is the wrong way to change Medicare

By Juliet Johnson  |    June 10, 2019
As Washington looks to make changes to Medicare, there are right ways and wrong ways to address the challenges patients face. In recent weeks, policymakers have discussed imposing government...   Read More

By the numbers: A look at the Part B International Pricing Index Model

By Nicole Longo  |    June 6, 2019
Mounting research continues to point to how international reference pricing schemes, like the Department of Health and Human Services’ (HHS) International Pricing Index (IPI) Model, could result...   Read More

How the rebate rule would help reduce patients’ out-of-pocket costs

By Tom Wilbur  |    June 3, 2019
The Department of Health and Human Services recently proposed a rule that would encourage using discounts negotiated between biopharmaceutical manufacturers and Part D plans to reduce patients’...   Read More

Event tomorrow: Improving access and affordability for America’s seniors

By Andrew Powaleny  |    May 7, 2019
Medicare Parts B and D have played an important role in providing seniors with access to the lifesaving treatments they need and have been successful in delivering value to both the health care...   Read More

Fact Check: How the Part B International Pricing Index Model replaces market competition with government-set prices

By Nicole Longo  |    May 3, 2019
One of the most common misconceptions about the administration’s proposed Part B International Pricing Index (IPI) Model is that it would improve competition in Medicare. However, mounting...   Read More

PhRMA comments on OIG proposed rule to reform the rebate system

By Holly Campbell  |    April 8, 2019
Today, PhRMA submitted comments on the Department of Health & Human Services (HHS) Office of Inspector General (OIG) proposed rule, “Removal of Safe Harbor Protection for Rebates Involving...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates